Fampridine(Dalfampridine)

Fampridine(Dalfampridine)
Product Description

  • Fampridine acts by blocking voltage-dependent potassium channels, thereby enhancing conduction in demyelinated nerve fibers.
  • Robust clinical trials have confirmed its ability to improve walking speed and overall mobility in multiple sclerosis patients.
  • Delivered in tablet form, ensuring convenient outpatient treatment and ease of use.
  • Clinical data indicate significant improvements in ambulation and quality of life.
  • Supported by a robust body of peer-reviewed research that underscores its therapeutic value.
  • EXAMON Handelsges.m.b.H.

    • AT
    • 2024
      On CPHI since
    • 3
      Certificates
    • 100 - 249
      Employees
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)
    Specifications
    • Details
      Oral Extended-Release Tablet: 10 mg
    • Selling Points
      Price; Product Features; Product Performance;
    • Oral Formulation
    • Affordability
    • Proven Impact
    • Stringent Quality
  • Model
    10 mg
  • EXAMON Handelsges.m.b.H.

    • AT
    • 2024
      On CPHI since
    • 3
      Certificates
    • 100 - 249
      Employees
    Company types
    Generics/Biosimilars Manufacturer
    Pharmaceutical company
    Primary activities
    API Producer
    Generic APIs producer
    Pharmaceutical Company (generic finished products)

    More Products from EXAMON Handelsges.m.b.H. (31)

    • Valganciclovir hydrochloride-API

      Product Valganciclovir hydrochloride-API

      • Premium-grade active pharmaceutical ingredient formulated for valganciclovir-based products • Supplied as a finely milled crystalline powder with exceptional purity and consistent quality • Produced under strict cGMP conditions to ensure reproducibility and high manufacturing standards • Extensively ...
    • Erlotinib-KIMOTAR®

      Product Erlotinib-KIMOTAR®

      • Erlotinib blocks the epidermal growth factor receptor’s tyrosine kinase to suppress tumor cell growth. • Validated efficacy in non-small cell lung cancer (first-line). • Offered in tablet form to facilitate patient-friendly, outpatient treatment. • Underpinned by a wide range of peer-reviewed studies...
    • Imatinib

      Product Imatinib

      • Targeted mechanism that selectively inhibits the BCR-ABL tyrosine kinase to disrupt signaling pathways driving abnormal cell growth in chronic myelogenous leukemia and gastrointestinal stromal tumors (first-line). • Clinically established with robust trials confirming its ability to control disease pro...
    • Gefitinib-GEFISA®

      Product Gefitinib-GEFISA®

      • Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. •  An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan...
    • Pazopanib-PAZOTRI®

      Product Pazopanib-PAZOTRI®

      • Inhibits multiple receptor tyrosine kinases, including VEGF, PDGF, and c-kit, to reduce tumor angiogenesis and growth. • Demonstrated clinical effectiveness in advanced renal cell carcinoma (second-line) and soft tissue sarcoma (second-line) through robust trials. • Administered orally, offering ...
    • Sunitinib-KITENT®

      Product Sunitinib-KITENT®

      • Multi-targeted tyrosine kinase inhibitor that blocks VEGF and PDGF receptors to hinder tumor angiogenesis and cell proliferation • Proven efficacy in advanced renal cell carcinoma (second-line), gastrointestinal stromal tumors (first-line), and pancreatic neuroendocrine tumors (second-line) • Administ...
    • Azacitidine-Kimia

      Product Azacitidine-Kimia

      • Incorporates into nucleic acids to induce DNA hypomethylation. • Clinically validated for myelodysplastic syndromes and AML. • Flexible administration via subcutaneous injection or IV infusion. • Established safety profile confirmed in rigorous clinical trials. • Demonstrated improvements in surviva...
    • Bortezomib-Kimia

      Product Bortezomib-Kimia

      • Inhibits the 26S proteasome, triggering targeted tumor cell apoptosis. • Clinically indicated for multiple myeloma and mantle cell lymphoma. • Offers flexible IV and subcutaneous administration options. • Demonstrated improvements in survival and quality of life. • Established, well-characterized sa...
    • Calcium folinate (levoleucovorin)-Kimia

      Product Calcium folinate (levoleucovorin)-Kimia

      • Supports DNA synthesis and repair while mitigating methotrexate toxicity. • Proven efficacy in enhancing fluorouracil therapy for colorectal cancer and serving as methotrexate rescue. • Enhances chemotherapeutic regimens to optimize patient outcomes. • Demonstrated tolerability and manageable adverse...
    • Carboplatin-Kimia

      Product Carboplatin-Kimia

      • Disrupts tumor DNA through crosslink formation to impede cell replication. • Widely validated in the treatment of various solid malignancies, including ovarian and lung cancers. • Administered via infusion to integrate seamlessly into contemporary oncology protocols. • Exhibits manageable adverse eff...
    • Cisplatin-Kimia

      Product Cisplatin-Kimia

      • Facilitates DNA crosslinking to inhibit replication and promote cancer cell apoptosis. • Demonstrates robust efficacy in various solid tumors, including testicular, ovarian, and bladder cancers. • Delivered via infusion, aligning with established oncology treatment protocols. • Often paired with othe...
    • Docetaxel-Kimia

      Product Docetaxel-Kimia

      • A potent taxane agent which stabilizes microtubules to disrupt cell division and promote apoptosis in malignant cells. • Demonstrated efficacy across various cancers including breast, lung, and prostate. • Seamlessly integrated into standard oncology treatment protocols. • Adverse effects are managea...

    Frequently Viewed Together

    Recently Visited